Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03054480
Other study ID # 109/1-59
Secondary ID
Status Completed
Phase N/A
First received February 11, 2017
Last updated February 15, 2017
Start date August 1, 2016
Est. completion date January 31, 2017

Study information

Verified date February 2017
Source Mae Fah Luang University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Because of the limiting data about an efficacy and safety of fractional radiofrequency for the treatment of hyperhidrosis, this study aim to compare clinical efficacy by Hyperhidrosis Disease Severity Score (HDSS) between Fractional Microneedle Radiofrequency device and intradermal Botulinum toxin type A injection for the treatment of primary axillary hyperhidrosis. The secondary objectives to determine the improvement change of iodine starch test, total amount of sweat production by trans-epidermal water loss (TEWL), patient's satisfaction and their quality of life by Dermatology Life Quality Index and side effect between the groups.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date January 31, 2017
Est. primary completion date December 31, 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

Male or female subjects, age between 18-60 years

- Healthy volunteers

- Subjects who have experienced with excessive sweating on both sides of axillary areas and have a positive result for iodine starch test on the screening day

- Willing to participant into the study and voluntary to sign in the informed consent form

Exclusion Criteria:

Active bacterial or fungal infection over tested area / axillae

- Pregnancy and breast feeding

- Previously underwent the surgical treatment such as radical resection of sweat glands for primary axillary hyperhidrosis

- Currently being treated with intradermal botulinum toxin type A injection at axillary area for less than 12 months

- Currently being inserted the cardiac pace maker or any other internal electronic devices

- Secondary hyperhidrosis caused by hyperthyroidism, drug induced, abnormal autonomic or neurological disorder that affect sweat gland

- Allergy to botulinum toxin type A

- Known contact allergy to iodine

- Unable to follow and comply to the study protocol

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Fractional Micro-Needle Radiofrequency

Drug:
Botulinum toxin type A


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Mae Fah Luang University Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary The change of Hyperhidrosis disease severity score (HDSS) at week-12 with the baseline Hyperhidrosis disease severity score will be assessed by study subjects that is categorized to 4 levels; (1) my axillary sweating is never noticeable and never interferes with my daily activities (2) my axillary sweating is tolerable but sometimes interferes with my daily activities (3) my axillary sweating is barely tolerable and frequently interferes with my daily activities (4) my axillary sweating is intolerable and always interferes with my daily activities 12 weeks
Secondary Iodine starch test Qualitative test used to evaluate sudo-motor function (sweating) which method is to apply iodine solution to the skin. Once dry, the area is dusted with cornstarch or potato flour then sweating is encouraged. When sweat reaches the surface of the skin the starch and iodine combine causing a dramatic color change from yellow to dark blue allowing sweat production to be actively visualized.
Photograph from iodine starch test will be assessed by two independent clinical assessors who are blinded to study protocol and grading with score. The investigators will prepare the photo with pre- and post-treatment set. Each set will contain 6 photos, 3 photos from the left and 3 photos from the right. Prepare by using Microsoft PowerPoint program, on each slide will contain 2 photos, pre-treatment photos on the left and post treatment photos on the right. The paired photos will be assessed and graded the score at different time points (4 and 12 weeks) on each side of axilla
baseline, week 4 and week 12
Secondary Participants' satisfaction assessment An assessment will be determined at the endpoint visit (4th-12thweek) after the treatment by study subjects by Quartile rating scale on each side of axilla. Quartile rating scale by comparing with the baseline that is categorized to 4 levels; (3) greatly satisfy with treatment result (2) moderately satisfy with treatment result (1) slightly satisfy with treatment result (0) No different with treatment result. week 4 and week 12
Secondary Adverse effect Side effect 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT03627468 - A Safety Study of BBI-4000 Gel in Patients With Axillary Hyperhidrosis Phase 3
Completed NCT03658616 - Assessment of Efficacy and Safety of Topical Administration of 1% Glycopyrronium Bromide (GPB) in Patients With Primary Axillary Hyperhidrosis and the Assessment of Long-term Efficacy and Safety of Topical Administration of 1% GPB Cream in Patients With Primary Axillary Hyperhidrosis. Phase 3
Completed NCT02286765 - Ulthera® System for Treating Axillary Hyperhidrosis N/A
Completed NCT04599907 - Evaluation of N-SWEAT Patch for Treatment of Primary Axillary Hyperhidrosis or Excessive Axillary Sweating N/A
Completed NCT03037788 - Investigation of Ascending Concentrations of Glycopyrronium Bromide (GPB) in a Topical Formulation in Subjects With Axillary Hyperhidrosis Phase 1
Terminated NCT01722461 - A Study of the Ulthera® System for the Treatment of Axillary Hyperhidrosis N/A
Completed NCT05863104 - Assessment of Safety, Tolerability, Systemic Exposure and Efficacy of GPB Cream in Adolescents With Severe Primary Hyperhidrosis Phase 2
Completed NCT02823340 - Fractionated Microneedle Radiofrequency for Treatment of Primary Axillary Hyperhidrosis N/A
Not yet recruiting NCT04159610 - Assessment of Safety, Tolerability and Efficacy of 1% GPB Cream Versus Qbrexza® (Glycopyrronium) Cloth 2.4% Under Maximum-Use Conditions in Subjects With Primary Axillary Hyperhidrosis Phase 2
Completed NCT01799824 - Clinical Trial to Evaluate ANT-1403 in the Treatment of Primary Axillary Hyperhidrosis Phase 2
Completed NCT03785587 - A Safety Study of BBI-4000 Gel in Pediatric Patients With Axillary Hyperhidrosis Phase 2